BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 32157887)

  • 1. Bifunctional Molecules beyond PROTACs.
    Conway SJ
    J Med Chem; 2020 Mar; 63(6):2802-2806. PubMed ID: 32157887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-Molecule Degraders beyond PROTACs-Challenges and Opportunities.
    Kastl JM; Davies G; Godsman E; Holdgate GA
    SLAS Discov; 2021 Apr; 26(4):524-533. PubMed ID: 33632029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted protein degradation and the enzymology of degraders.
    Fisher SL; Phillips AJ
    Curr Opin Chem Biol; 2018 Jun; 44():47-55. PubMed ID: 29885948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives on the development of first-in-class protein degraders.
    Rambacher KM; Calabrese MF; Yamaguchi M
    Future Med Chem; 2021 Jul; 13(14):1203-1226. PubMed ID: 34015962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PROTACs: New method to degrade transcription regulating proteins.
    Hu B; Zhou Y; Sun D; Yang Y; Liu Y; Li X; Li H; Chen L
    Eur J Med Chem; 2020 Dec; 207():112698. PubMed ID: 32858471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
    Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
    Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PROTAC-DB: an online database of PROTACs.
    Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
    Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small-molecule PROTACs: novel agents for cancer therapy.
    Wan Y; Yan C; Gao H; Liu T
    Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
    Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
    Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.
    Maniaci C; Hughes SJ; Testa A; Chen W; Lamont DJ; Rocha S; Alessi DR; Romeo R; Ciulli A
    Nat Commun; 2017 Oct; 8(1):830. PubMed ID: 29018234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents.
    Coll-Martínez B; Delgado A; Crosas B
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33339292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications.
    Ward CC; Kleinman JI; Brittain SM; Lee PS; Chung CYS; Kim K; Petri Y; Thomas JR; Tallarico JA; McKenna JM; Schirle M; Nomura DK
    ACS Chem Biol; 2019 Nov; 14(11):2430-2440. PubMed ID: 31059647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective targeting of non-centrosomal AURKA functions through use of a targeted protein degradation tool.
    Wang R; Ascanelli C; Abdelbaki A; Fung A; Rasmusson T; Michaelides I; Roberts K; Lindon C
    Commun Biol; 2021 May; 4(1):640. PubMed ID: 34050235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives.
    Wang C; Zhang Y; Wang J; Xing D
    Eur J Med Chem; 2022 Jan; 227():113906. PubMed ID: 34656901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-Throughput Quantitative Assay Technologies for Accelerating the Discovery and Optimization of Targeted Protein Degradation Therapeutics.
    Simard JR; Lee L; Vieux E; Improgo R; Tieu T; Phillips AJ; Fisher SL; Pollock RM; Park E
    SLAS Discov; 2021 Apr; 26(4):503-517. PubMed ID: 33430712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Vital Role of Proteomics in Characterizing Novel Protein Degraders.
    Zhang AX; Cassidy K; Dahl G; Moreau K; Pachl F; Zuhl AM
    SLAS Discov; 2021 Apr; 26(4):518-523. PubMed ID: 33615886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway.
    Collins I; Wang H; Caldwell JJ; Chopra R
    Biochem J; 2017 Mar; 474(7):1127-1147. PubMed ID: 28298557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.
    Smith BE; Wang SL; Jaime-Figueroa S; Harbin A; Wang J; Hamman BD; Crews CM
    Nat Commun; 2019 Jan; 10(1):131. PubMed ID: 30631068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action.
    Riching KM; Mahan S; Corona CR; McDougall M; Vasta JD; Robers MB; Urh M; Daniels DL
    ACS Chem Biol; 2018 Sep; 13(9):2758-2770. PubMed ID: 30137962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins.
    Buckley DL; Raina K; Darricarrere N; Hines J; Gustafson JL; Smith IE; Miah AH; Harling JD; Crews CM
    ACS Chem Biol; 2015 Aug; 10(8):1831-7. PubMed ID: 26070106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.